离开Neuralink后，麦克斯・霍达克在打造更离奇的东西

Core Insights - The article discusses the advancements and ambitions of Science Corp, particularly in the field of brain-computer interface (BCI) technology, led by CEO Max Hodak, who previously co-founded Neuralink [1][2][3] Company Overview - Science Corp was founded by Max Hodak and three former Neuralink colleagues approximately four years ago, aiming to create innovative BCI solutions [2][3] - The company is focused on generating revenue by manufacturing and selling tools for researchers, transforming expensive systems into affordable devices [3][19] Product Development - The initial commercial product, named Prima, involves a tiny computer chip implanted in the retina to restore vision for patients with late-stage macular degeneration, achieving an 80% success rate in clinical trials [4][20] - The company acquired the Prima technology from Pixium Vision and has optimized it for clinical trials, with plans to launch in Europe next summer [4][20] Future Innovations - Science Corp is exploring optogenetic gene therapy to make neurons light-sensitive, aiming to eliminate the need for electrodes in BCI applications [5][21][22] - The company is also investigating the potential to cultivate new brain tissue, which could overcome limitations associated with traditional electrode technology [7][23] Long-term Vision - Hodak envisions that BCI technology could eventually lead to the creation of conscious machines, addressing the fundamental nature of consciousness and its implications for human experience [10][24][25] - By 2035, Hodak predicts that BCI technology will be available for patients, potentially allowing for consciousness uploading as a treatment option for terminal illnesses [12][26] Economic Implications - The article highlights concerns about the economic model of healthcare as BCI technology becomes more prevalent, suggesting that it may lead to increased healthcare costs and a divide between wealthy and less affluent individuals [14][27] - Hodak argues that while consumer technology tends to become cheaper and more accessible, the healthcare sector operates under a fixed funding model that may not sustain the rising costs associated with advanced BCI technologies [14][27]